Cargando…

Anlotinib Alone or in Combination With Temozolomide in the Treatment of Recurrent High-Grade Glioma: A Retrospective Analysis

Background: Anlotinib is a multi-target anti-angiogenic agent. This retrospective study aimed to evaluate the efficacy and safety of anlotinib alone or in combination with temozolomide for the treatment of recurrent high-grade glioma. Materials and Methods: The clinical data of patients with recurre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Qunying, Guo, Chengcheng, Lin, Xiaoping, Luo, Lili, He, Zhenqiang, Lin, Fuhua, Zhang, Ji, Chen, Yinsheng, Jiang, Xiaobing, Ke, Chao, Mou, Yonggao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8741259/ https://www.ncbi.nlm.nih.gov/pubmed/35002738 http://dx.doi.org/10.3389/fphar.2021.804942

Ejemplares similares

External Validation of a Nomogram and Risk Grouping System for Predicting Individual Prognosis of Patients With Medulloblastoma
por: Guo, Chengcheng, et al.
Publicado: (2020)

SYST-04 PRELIMINARY REPORT OF A CLINICAL TRIAL EVALUATING THE SAFETY AND EFFICIENCY OF NEOADJUVANT CAMRELIZUMAB AND APATINIB IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMAS: A PROSPECTIVE, PHASE II, SINGLE-ARM STUDY
por: Lin, Fuhua, et al.
Publicado: (2022)

Anlotinib as Monotherapy or Combination Therapy for Recurrent High-Grade Glioma: A Retrospective Study
por: Yin, Jun, et al.
Publicado: (2023)

Temozolomide and Reirradiation in Recurrent Grade II Brain Glioma
por: Osman, Mohammed A
Publicado: (2014)

TIPS-13 A PHASE II STUDY OF NEOADJUVANT CAMRELIZUMAB AND APATINIB IN PATIENTS WITH RECURRENT HIGH-GRADE GLIOMAS
por: Guo, Chengcheng, et al.
Publicado: (2023)

TRLS-04. A Nomogram for Predicting Survival in Patients with Brain Metastases
por: Wang, Zhenning, et al.
Publicado: (2021)

Outcome of surgical resection for brain metastases and radical treatment of the primary tumor in Chinese non–small-cell lung cancer patients
por: Li, Zhenye, et al.
Publicado: (2015)

Retrospective Study of the Safety and Efficacy of Anlotinib Combined With Dose-Dense Temozolomide in Patients With Recurrent Glioblastoma
por: She, Lei, et al.
Publicado: (2021)

The Efficacy and Safety of Anlotinib in Pediatric Patients With Refractory or Recurrent Solid Tumors
por: Lu, Suying, et al.
Publicado: (2022)

CARD-Associated Risk Score Features the Immune Landscape and Predicts the Responsiveness to Anti-PD-1 Therapy in IDH Wild-Type Gliomas
por: Li, Depei, et al.
Publicado: (2021)

Effect of anlotinib combined with ticeorgio for recurrent nasopharyngeal carcinoma: a case report
por: Mao, Jiwei, et al.
Publicado: (2023)

TIPS-05 ADJUVANT TEMOZOLOMIDE CHEMOTHERAPY FOLLOWING RADIOTHERAPY IN NEWLY DIAGNOSED LOW-GRADE GLIOMA PATIENT WITH RESIDUE TUMORS: A MULTICENTER, OPEN LABEL, RANDOMIZED TRIAL
por: Chen, Zhongping, et al.
Publicado: (2023)

High preoperative albumin-bilirubin score predicts poor survival in patients with newly diagnosed high-grade gliomas
por: Zhang, Jie, et al.
Publicado: (2021)

Anlotinib combined with temozolomide for the treatment of patients with diffuse midline glioma: a case report and literature review
por: Feng, Yiping, et al.
Publicado: (2022)

Recurrence patterns in patients with high-grade glioma following temozolomide-based chemoradiotherapy
por: Zhou, Xiaofeng, et al.
Publicado: (2016)

Hypertensive Retinopathy Secondary to Anlotinib Treatment
por: Zhang, Xiaohua, et al.
Publicado: (2020)

Knockdown lncRNA DLEU1 Inhibits Gliomas Progression and Promotes Temozolomide Chemosensitivity by Regulating Autophagy
por: Lv, Qiao-Li, et al.
Publicado: (2020)

GCT-30. TREATMENT OF PRIMARY INTRACRANIAL GERM CELL TUMORS: SINGLE INSTITUTION EXPERIENCE OF 74 CASES WITHOUT HISTOLOGICAL CONFIRMATION
por: Guo, Chengcheng, et al.
Publicado: (2020)

Almonertinib Combined with Anlotinib and Temozolomide in a Patient with Recurrent Glioblastoma with EGFR L858R Mutation
por: Hou, Zhiwei, et al.
Publicado: (2023)

Depatux-M and temozolomide in advanced high-grade glioma
por: Hirsch, Sophie, et al.
Publicado: (2020)

Efficacy of apatinib combined with temozolomide in the treatment of recurrent high‑grade glioma: A meta‑analysis
por: Li, Guanglie, et al.
Publicado: (2023)

Temozolomide Chemotherapy in Patients with Recurrent Malignant Gliomas
por: Yang, Seung-Ho, et al.
Publicado: (2006)

Survival impacts of extent of resection and adjuvant radiotherapy for the modern management of high-grade meningiomas
por: Li, Depei, et al.
Publicado: (2019)

Dynamic analysis of immune status in patients with intracranial germ cell tumor and establishment of an immune risk prognostic model
por: Wang, Hairong, et al.
Publicado: (2022)

Efficacy and safety of pharmacotherapy for recurrent high-grade glioma: a systematic review and network meta-analysis
por: Xu, Yanan, et al.
Publicado: (2023)

The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: A retrospective analysis
por: Shen, Fangcheng, et al.
Publicado: (2023)

Temozolomide and Radiotherapy versus Radiotherapy Alone in High Grade Gliomas: A Very Long Term Comparative Study and Literature Review
por: Parisi, Salvatore, et al.
Publicado: (2015)

TIPS-12 PHASE I CLINICAL STUDY OF TG02 CAPSULE IN THE TREATMENT OF RECURRENT HIGH-GRADE GLIOMAS WITH FAILED TMZ TREATMENT
por: Guo, Chengcheng, et al.
Publicado: (2023)

Identification of a Twelve-Gene Signature and Establishment of a Prognostic Nomogram Predicting Overall Survival for Medulloblastoma
por: Zhu, Sihan, et al.
Publicado: (2020)

Integrating bulk and single-cell RNA sequencing data reveals epithelial-mesenchymal transition molecular subtype and signature to predict prognosis, immunotherapy efficacy, and drug candidates in low-grade gliomas
por: Wang, Chengcheng, et al.
Publicado: (2023)

The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Previously Treated Advanced Thymic Epithelia Tumors: A Retrospective Analysis
por: Li, Shuo, et al.
Publicado: (2023)

Comparison of long-term survival between temozolomide-based chemoradiotherapy and radiotherapy alone for patients with low-grade gliomas after surgical resection
por: Gai, Xiu-juan, et al.
Publicado: (2016)

Anlotinib Inhibits PFKFB3-Driven Glycolysis in Myofibroblasts to Reverse Pulmonary Fibrosis
por: Chen, Weimou, et al.
Publicado: (2021)

Temozolomide in paediatric high-grade glioma: a key for combination therapy?
por: Verschuur, A C, et al.
Publicado: (2004)

SCD1 Confers Temozolomide Resistance to Human Glioma Cells via the Akt/GSK3β/β-Catenin Signaling Axis
por: Dai, Shuang, et al.
Publicado: (2018)

Preoperative Changes in Hematological Markers and Predictors of Glioma Grade and Survival
por: Wang, Peng-Fei, et al.
Publicado: (2018)

Pre-treatment or Post-treatment of Human Glioma Cells With BIX01294, the Inhibitor of Histone Methyltransferase G9a, Sensitizes Cells to Temozolomide
por: Ciechomska, Iwona Anna, et al.
Publicado: (2018)

Corrigendum: SCD1 Confers Temozolomide Resistance to Human Glioma Cells Via the Akt/GSK3β/β-Catenin Signaling Axis
por: Dai, Shuang, et al.
Publicado: (2019)

Temozolomide in malignant glioma
por: Dresemann, Gregor
Publicado: (2010)

Monitoring temozolomide treatment of low-grade glioma with proton magnetic resonance spectroscopy
por: Murphy, P S, et al.
Publicado: (2004)

Cannot write session to /tmp/vufind_sessions/sess_ene23ki8u6j4d46dejt1eid6u6